Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemiaCatherine C. Smith, Neil P. Shah, Qi Wang et al.|Nature|2012Cited by 745
Crenolanib is a selective type I pan-FLT3 inhibitorCatherine C. Smith, Neil P. Shah, Elisabeth A. Lasater et al.|Proceedings of the National Academy of Sciences|2014Cited by 211
NPM1 mutation is associated with leukemia cutis in acute myeloid leukemia with monocytic featuresMarlise R. Luskin, Alexander E. Perl, Auris Huen et al.|Haematologica|2015Cited by 34
Characteristics and outcome of patients with core-binding factor acute myeloid leukemia and FLT3-ITD: results from an international collaborative studySabine Käyser, Mark J. Levis, David Martínez‐Cuadrón et al.|Haematologica|2021Cited by 34
Gilteritinib Results in Higher Remission and Transplant Rates Than Midostaurin but Does Not Increase the Post-Induction Mutational MRD Negative Rate: Results of the Phase 2 Randomized Precog 0905 Study in Newly Diagnosed <i>FLT3</i> Mutated AMLSelina M. Luger, Mark R. Litzow, Li Chen et al.|Blood|2024Cited by 7